Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose nebulised GSK2862277 to prevent peri-operative lung injury in oesophagectomy
2014-000643-33Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2014
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) and Perioperative lung injury (PLI) comparing GSK2862277 nebulised single dose with Placebo nebulised single dose (2 arms). Primary endpoint: Baseline adjusted change in Pulmonary Vascular Permeability Index on completion of surgery. Started Jul 2014; status: terminated.
02
Drugs
GSK2862277
03
Conditions
acute respiratory distress syndrome (ARDS)Perioperative lung injury (PLI)
Beyond the preview
Go deeper on 2014-000643-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000643-33.